ArticleHepatology (Baltimore, Md.)2026
Causes of mortality among patients with early-stage hepatocellular carcinoma.
Article in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and Validation of a Machine Learning Model to Prognosticate Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2026Article
- Multi-Target HCC Blood Test Demonstrates Consistent Performance Across Subgroups of Patients with Chronic Liver Disease.Cancers · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND AND
aimsEarly detection of hepatocellular carcinoma (HCC) can reduce cancer-related mortality; however, there are often competing risks from comorbid conditions, including cirrhosis. Understanding causes of death among patients with early-stage HCC can inform strategies to improve surveillance effectiveness. APPROACH AND
resultsWe conducted a retrospective cohort study of patients with early-stage HCC [Barcelona Clinic Liver Cancer (BCLC) stages 0/A] at 4 U.S. health systems between 2008 and 2022. We defined the primary cause of death as HCC-related, liver-related (non-HCC), and death from other causes. We used multivariable and Fine-Gray analysis, with liver transplant as a competing outcome, to identify factors associated with mortality. Among 1336 patients with early-stage HCC, 598 (44.8%) died during a median follow-up of 32.4 months-220 (37%) HCC-related, 114 (19%) liver-related, and 179 (30%) from other causes. Median time to death was similar between the groups: 24 (95% CI 22-31), 19 (95% CI 15-23), and 23 (95% CI 19-27) months for HCC-related, liver-related, and other causes of mortality, respectively. Curative treatment was associated with reduced HCC-related (HR 0.34; 95% CI 0.23-0.48) and liver-related mortality (HR 0.23; 95% CI 0.14-0.38). Predictors of HCC-related mortality included alpha-fetoprotein (AFP) >20 ng/mL (HR 2.19; 95% CI 1.59-3.03) and tumor diameter >3 cm (HR 1.69; 95% CI 1.20-2.37). Liver-related mortality was associated with MASLD (metabolic dysfunction-associated steatotic liver disease) etiology (HR 1.99; 95% CI 1.09-3.65), Child-Pugh B cirrhosis (HR 2.64; 95% CI 1.58-4.42), and Albumin-Bilirubin (ALBI) grade 2 (vs. grade 1: HR 2.47; 95% CI 1.21-5.06).
conclusionsCause of death varies among patients with early-stage HCC, although HCC-related death remains the most common cause. Efforts are needed to optimize curative treatment effectiveness among patients with early-stage HCC to reduce cancer-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.